Cercare il medicinale per il nome

Tetracon e Disfunzione renale

Risultato del controllo d'interazione tra il farmaco Tetracon e la malattia Disfunzione renale su sicurezza in caso d'uso simultaneo.

Risultato di controllo:

Tetracon <> Disfunzione renale

Rilevanza: 23.07.2019 Recensore: P.M. Shkutko, dott., in

Durante il controllo d'interazione, secondo le fonti autorevoli Drugs.com, Rxlist.com, Webmd.com, Medscape.com sono trovate le controindicazioni o gli effetti collaterali che possono danneggiare oppure intensificare l’effetto negativo in caso d'uso del farmaco in presenza di questa malattia concomitante.

Consumatore:

Tetracicline (ad eccezione di doxiciclina) sono eliminati per via renale di vario grado. Pazienti con compromissione della funzionalità renale possono essere a maggior rischio di tetracycline associata a insufficienza epatica e/o tossicità renale (aumento del BUN con conseguente azotemia, iperfosfatemia, e acidosi) a causa della diminuzione di liquidazione droga. La terapia con tetracicline deve essere somministrato con cautela a dosaggi ridotti in pazienti con insufficienza renale. Il monitoraggio clinico della funzionalità renale ed epatica si raccomanda un siero a base di tetraciclina livelli possono essere necessarie durante una terapia prolungata.

Fonte

Lee P, Crutch ER, Morrison RB, et al "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972): 355-8
Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981): 396
Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985): 270-7
Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978): 233-9
"Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.
"Product Information. Vibramycin (doxycycline)." Pfizer US Pharmaceuticals, New York, NY.
George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971): 1271-3
Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980): 2513-5
Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982): 137-45
Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977): 195-7
"Product Information. Terramycin (oxytetracycline)." Pfizer US Pharmaceuticals, New York, NY.
Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988): 355-66
Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967): 433-5
Whelton A, von Wittenau MS, Twomey TM, et al "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974): 365-71
"Product Information. Minocin (minocycline)." Lederle Laboratories, Wayne, NJ.
"Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.
Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974): 299-308
Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978): 616
Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963): 389-408
Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977): 369-77
Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978): 223-36
Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977): 52
Houin G, Brunner F, Nebout T, et al "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983): 245-52
Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973): 318-24
Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975): 532-7
Macdonald H, Kelly RG, Allen ES, et al "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973): 852-61
Mahon WA, Johnson GE, Endrenyi L, et al "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976): 24-31
Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975): 251-91